PL2303020T3 - Otrzymywanie postaci dawkowania środka zwiotczającego mięśnie szkieletowe o kontrolowanym uwalnianiu - Google Patents

Otrzymywanie postaci dawkowania środka zwiotczającego mięśnie szkieletowe o kontrolowanym uwalnianiu

Info

Publication number
PL2303020T3
PL2303020T3 PL09767735T PL09767735T PL2303020T3 PL 2303020 T3 PL2303020 T3 PL 2303020T3 PL 09767735 T PL09767735 T PL 09767735T PL 09767735 T PL09767735 T PL 09767735T PL 2303020 T3 PL2303020 T3 PL 2303020T3
Authority
PL
Poland
Prior art keywords
preparation
dosage forms
controlled release
skeletal muscle
muscle relaxant
Prior art date
Application number
PL09767735T
Other languages
English (en)
Inventor
Gopi Venkatesh
James M. Clevenger
Timothy Grinstead
Original Assignee
Adare Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41434443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2303020(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adare Pharmaceuticals, Inc. filed Critical Adare Pharmaceuticals, Inc.
Publication of PL2303020T3 publication Critical patent/PL2303020T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09767735T 2008-06-20 2009-06-18 Otrzymywanie postaci dawkowania środka zwiotczającego mięśnie szkieletowe o kontrolowanym uwalnianiu PL2303020T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7446408P 2008-06-20 2008-06-20
EP09767735.5A EP2303020B1 (en) 2008-06-20 2009-06-18 Preparation of controlled release skeletal muscle relaxant dosage forms

Publications (1)

Publication Number Publication Date
PL2303020T3 true PL2303020T3 (pl) 2017-08-31

Family

ID=41434443

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09767735T PL2303020T3 (pl) 2008-06-20 2009-06-18 Otrzymywanie postaci dawkowania środka zwiotczającego mięśnie szkieletowe o kontrolowanym uwalnianiu

Country Status (28)

Country Link
US (3) US20090148532A1 (pl)
EP (1) EP2303020B1 (pl)
JP (1) JP5636364B2 (pl)
KR (1) KR101451823B1 (pl)
CN (2) CN102065691A (pl)
AR (2) AR072267A1 (pl)
AU (1) AU2009259993B2 (pl)
BR (1) BRPI0914225B1 (pl)
CA (1) CA2727935C (pl)
CL (1) CL2009001447A1 (pl)
CO (1) CO6300903A2 (pl)
CR (1) CR11864A (pl)
CY (1) CY1118878T1 (pl)
DK (1) DK2303020T3 (pl)
ES (1) ES2625485T3 (pl)
HU (1) HUE032182T2 (pl)
IL (1) IL209997A0 (pl)
MX (1) MX2010013760A (pl)
MY (2) MY173408A (pl)
NZ (1) NZ589856A (pl)
PL (1) PL2303020T3 (pl)
PT (1) PT2303020T (pl)
RU (1) RU2540494C2 (pl)
SG (1) SG193816A1 (pl)
TW (2) TW201503915A (pl)
UY (1) UY31928A (pl)
WO (1) WO2009155426A1 (pl)
ZA (2) ZA201009083B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
WO2010133961A1 (en) * 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
EP2501234B1 (en) * 2009-11-20 2017-09-13 Tonix Pharma Holdings Limited Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
US20150086626A1 (en) * 2012-04-17 2015-03-26 Mylan, Inc Stable dosage forms of skeletal muscle relaxants with extended release coating
PT2861223T (pt) * 2012-06-15 2022-11-07 Tonix Pharmaceuticals Inc Composições e métodos de absorção transmucosa
EP2968992B8 (en) 2013-03-15 2020-01-15 Tonix Pharma Holdings Limited Eutectic formulations of cyclobenzaprine hydrochloride and mannitol
CN107072968B (zh) 2014-09-18 2021-01-12 通尼克斯制药控股有限公司 环苯扎林盐酸盐的低共熔混合物配制剂
EP3592337B1 (en) * 2017-03-08 2023-07-05 Cinrx Pharma, LLC Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EP3723860A1 (en) 2017-12-11 2020-10-21 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN109381446A (zh) * 2018-11-26 2019-02-26 正大制药（青岛）有限公司 一种盐酸环苯扎林缓释胶囊
CN111374942B (zh) * 2018-12-30 2022-09-13 鲁南制药集团股份有限公司 一种甾体类肌松药注射液及其制备方法
CN114432266B (zh) * 2021-12-23 2023-03-10 南通联亚药业股份有限公司 一种稳定的盐酸环苯扎林缓释胶囊

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3882246A (en) * 1971-05-21 1975-05-06 Merck & Co Inc Treatment of skeletal muscle disorders with cyclobenzaprine
US4337582A (en) * 1980-09-30 1982-07-06 Airco, Inc. Methods for controlling vapor concentrations in an atmosphere
US4685918A (en) 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US5047258A (en) 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
CN100391438C (zh) * 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
US6576702B2 (en) 2000-07-20 2003-06-10 Noveon Ip Holdings Corp. Plasticized waterborne polyurethane dispersions and manufacturing process
CA2481236A1 (en) 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
WO2005041935A1 (en) 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
US20060263429A1 (en) * 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
AU2007230546A1 (en) * 2006-03-24 2007-10-04 Panacea Biotec Ltd. Antibiotic compositions of modified release and process of production thereof
US20090148532A1 (en) 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms

Also Published As

Publication number Publication date
JP2011525188A (ja) 2011-09-15
AU2009259993B2 (en) 2013-10-31
CY1118878T1 (el) 2018-01-10
US8137734B2 (en) 2012-03-20
CO6300903A2 (es) 2011-07-21
IL209997A0 (en) 2011-02-28
CL2009001447A1 (es) 2009-08-21
AR113877A2 (es) 2020-06-24
EP2303020A4 (en) 2013-12-04
EP2303020B1 (en) 2017-02-22
US20090148532A1 (en) 2009-06-11
MY173408A (en) 2020-01-22
BRPI0914225A2 (pt) 2017-11-07
NZ589856A (en) 2012-06-29
AU2009259993A1 (en) 2009-12-23
CN102065691A (zh) 2011-05-18
RU2540494C2 (ru) 2015-02-10
US20100098832A1 (en) 2010-04-22
EP2303020A1 (en) 2011-04-06
TW201004615A (en) 2010-02-01
JP5636364B2 (ja) 2014-12-03
AR072267A1 (es) 2010-08-18
BRPI0914225A8 (pt) 2018-02-06
CA2727935A1 (en) 2009-12-23
KR101451823B1 (ko) 2014-10-16
UY31928A (es) 2010-01-29
TWI458480B (zh) 2014-11-01
MX2010013760A (es) 2011-03-29
ZA201009083B (en) 2012-03-28
ES2625485T3 (es) 2017-07-19
CN106860430A (zh) 2017-06-20
WO2009155426A1 (en) 2009-12-23
RU2011101918A (ru) 2012-07-27
MY153712A (en) 2015-03-13
BRPI0914225B1 (pt) 2021-08-31
SG193816A1 (en) 2013-10-30
US20120196028A1 (en) 2012-08-02
ZA201109534B (en) 2013-10-30
HUE032182T2 (en) 2017-09-28
CR11864A (es) 2011-05-16
DK2303020T3 (en) 2017-05-01
PT2303020T (pt) 2017-06-02
KR20110025654A (ko) 2011-03-10
TW201503915A (zh) 2015-02-01
CA2727935C (en) 2017-05-30

Similar Documents

Publication Publication Date Title
ZA201109534B (en) Preparation of controlled release skeletal muscle relaxant dosage forms
HK1155712A1 (en) Controlled release of microbiocides
HRP20171421T1 (hr) Kruti oblici doziranja bendamustina
IL201008A0 (en) Modified release dosage forms of tacrolimus
ZA201103938B (en) Process for the preparation of a fat continuous spread
HRP20181854T1 (hr) Farmaceutski pripravak sporog oslobađanja pripremljen od mikročestica
HK1145806A1 (en) Extended release formulation of nevirapine
EP2370414A4 (en) PREPARATION OF CAPECITABINE
EP2217065A4 (en) PREPARATION OF SATURATED IMIDAZOLINIUM SALTS AND RELATED COMPOUNDS
EP2358693A4 (en) PREPARATION OF DOCETAXEL
TWI367205B (en) Preparation of paricalcitol
IL187443A0 (en) Game of chance
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
GB0717955D0 (en) Preparation of modified nucleosides
PL384675A1 (pl) Nowe zastosowanie preparatu probiotycznego